Study Of Relative Bioavailability/bioequivalence Of Two Formulations Of Rosuvastatin Calcium In Healthy Volunteers For Both Sexes [estudo De Biodisponibilidade Relativa/bioequivalência De Duas Formulações De Rosuvastatina Cálcica Em Voluntários Sadios De Ambos Os Sexos]

The study was conducted to compare the bioavailability of two formulations of rosuvastatin calcium 20 mg tablet (rosuvastatin calcium of Aché S/A test formulation and Crestor® from AstraZeneca do Brasil Ltda. reference formulation, Brazil) in 24 volunteers both sexes. This was an open, randomized, two-sequence, two-period, crossover single dose two treatments, in which a group of volunteers received the test formulation and the other reference formulation. Blood samples were obtained throughout a 96 hours interval. The rosuvastatin calcium concentrations were determined by mass spectrometry (UPLC-MS-MS) using atorvastatin as internal standard. From the data obtained, calculate the following pharmacokinetic parameters: AUC 0-t, AUC 0-∞ and Cmax. The geometric mean of rosuvastatin calcium/Crestor® 20 mg were 93,97% for AUC 0-t, 97,43% for AUC 0-∞ and 93,63% for Cmax. The 90% confidence intervals were 82,26-107,34%, 85,82-110,61% and 81,58-107,45%, respectively. Since the confidence intervals 90% for Cmax and AUC 0-t was within the range 80-125% proposed by the FDA and ANVISA (National Agency of Sanitary Surveillance in Brazil), it is concluded that the tablet of rosuvastatin calcium 20 mg was bioequivalent to Crestor® tablet of 20 mg and thus the test product may be considered interchangeable in medical practice. © Copyright Moreira Jr. Editora.697167172Moghadasian, M.H., Experimental atherosclerosis: A historical overview (2002) Life Sci, 70, pp. 855-865Kritchevsky, D., Dietary protein, cholesterol and atherosclerosis: A review of the early history (1995) J Nutr, 125, pp. 587-593Lichtman, A.H., Clinton, S.K., Iyama, K., Connelly, P.W., Libby, P., Cybulsky, M.I., Hyperlipidemia and atherosclerotic lesion development in LDL receptor deficient mice fed defined semipurified diets with and without cholate (1999) Arterioscler Thromb Vasc Biol, 19, pp. 1938-1944Melo, F.S., Toledo, J.C.Y., Coca, A.P., Junior, H.M., Hipertensão arterial, aterosclerose e inflamação: O endotélio como órgäo-alvo (2007) Rev Bras Hipertens, 14, pp. 234-238Michael, P., Christopher, P., Use of lipid lowering drugs for primary prevention of coronary heart disease: Meta-analysis of randomised trials (2000) BMJ, 321, p. 983Forti, N., Diament, J., Efeitos indesejáveis dos hipolipemiantes: Condutas na prática clínica (2008) Rev Assoc Med Bras, 54 (357), p. 362Davignon, J., Beneficial cardiovascular pleiotropic effects of statins (2004) Circulation, 109, pp. 39-43Wassmann, S., Laufs, U., Baumer, A.T., HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species (2001) Hypertension, 37, pp. 1450-1457Kwak, B., Mulhaupt, F., Myit, S., Mach, F., Statins as a newly recognized type of immunomodulator (2000) Nature Medicine, 6, pp. 1399-1402Mason, J.C., Statins and their role in vascular protection (2003) Clinical Science, 105, pp. 251-266Masato, E., Kozai, T., Cosentino, F., Statin prevents tissue factor expression in human endothelial cells. Role of Rho/Rho-kinase and AKT pathways (2002) Circulation, 105, pp. 1756-1759Ichiki, T., Takeda, K., Todunou, T., Down regulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzima A reductase inhibitors in vascular smooth muscle cells (2001) Arterioscl Thromb Vasc Biol, 21, pp. 1896-1901Walter, D.H., Rittig, K., Bahlmann, F.H., Statin therapy acelerates reendothelization: A novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells (2002) Circulation, 105, pp. 3017-3024Harper, C.R., Jacobson, T.A., The broad spectrum of statin myopathy: From myalgia to rhabdomyolysis. Hyperlipidaemia and cardiovascular disease (2007) Current Opinion in Lipidology, 18, pp. 401-408Taggart, F., Buckett, L., Davidson, R., Holdgate, G., McCormick, A., Schneck, D., Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reducatase inhibitor (2001) Am J Cardiol, 87, pp. 28-32Buckett, L., Ballard, P., Davidson, R., Dunkley, C., Martin, L., Stafford, J., Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versu non-hepatic cells (2000) Atherosclerosis Supplements, 141, p. 151Brown, C.D.A., Windass, A., Bleasby, A., Lauffart, B., Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C (2001) Atherosclerosis Supplements, 2, p. 90Smith, G., Davidson, R., Bloor, S., Burns, K., Calnam, C.C., Aulay, P.M.C., Pharmacological properties of ZD4522 - A new HMG-CoA reductase inhibitor (2000) Atherosclerosis Supplements, 139, p. 151Schuster, H., Rosuvastatin-a highly effective new 3-hydroxy-3-methylglutaryl Coenzyme. A reductase inhibitor: Review of clinical trial data at 10-40 mg doses in dyslipidemic patients (2003) Cardiology, 99, pp. 126-139Jones, P.H., Davidson, M.H., Stein, E.A., Bays, H.E., Mckenney, J.M., Miller, E., Comparison of efficacy and safety of rosuvastatin versus atorvastatin. Simvastatin, and pravastatin across doses (2003) Am J Cardiol, 92, pp. 152-160Chapman, M.J., Taggart, F., Optimizing the pharmacology of statins: Characteristics of rosuvastatin (2002) Atherosclerosis Supplements, 2, pp. 33-36Cooper, K.J., Martin, P.D., Dane, A.L., Warwick, M.J., Raza, A., Schneck, D.W., Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects (2003) Br J Clin Pharmacol, 55, pp. 94-99Schneck, D.W., Knopp, R.H., Ballantyne, C.M., McPherson, R., Chitra, R.R., Simonson, S.G., Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease (2003) Am J Cardiol, 91, pp. 33-41Blasetto, J.W., Stein, E.A., Brown, W.V., Chitra, R., Raza, A., Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemia patients and in special population groups (2003) Am J Cardiol, 91, pp. 3-10Shepherd, J., Hunninghake, D.B., Barter, P., McKenney, J.M., Hutchinson, H.G., Guidelines for lowering lipids to reduce coronary artery disease risk: A comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid lowering goals (2003) Am J Cardiol, 91, pp. 11-19Davidson, M., Ma, P., Stein, E.A., Gotto, A.M., Raza, J.A., Chitra, R., Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or Iib hypercholesterolemia (2002) Am J Cardiol, 89, pp. 268-275Ballantyne, C.M., Stein, E.A., Paoletti, R., Southworth, H., Blasetto, J.W., Efficacy of rosuvastatin 10mg in patients with the metabolic syndrome (2003) Am J Cardiol, 91, pp. 25-28Moghadasian, M.H., Mancini, G.B.J., Frohlich, J.J., Pharmacotherapy of hyperchcholesterolaemia: Statins in clinical practice (2000) Exp Opin Pharmacother, 1, pp. 683-695Rader, D.J., Davidson, M.H., Caplan, R.J., Pears, J.S., Lipid and apolipoprotein ratios:association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin and simvastatin (2003) Am J Cardiol, 91, pp. 20-24Istvan, E.S., Deisenhofer, J., Structural Mechanism for statin inhibition of HMG-CoA reductase (2001) Science, 292, pp. 1160-1164Oliveira, C.M., Dislipidemias (2011) RBM. Rev. Bras. Med., 68, pp. 42-60Cheung, B.M.Y., Lauder, I.J., Lau, C., Rumana, C.R., Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes (2004) Br J Clin Pharmacol, 57, pp. 640-651Cheng-Lai, A., Rosuvastatin: A new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia (2003) Heart Disease, 5, pp. 72-78Kemp, J., Martin, P., Olive, M.D., Coadministration of rosuvastatin does not alter the pharmacokinetics of digoxin (2001) Pharmacotherapy, 21, p. 1255Coelho, V.G., Perfil lipídico e fatores de risco para doenças cardiovasculares em estudantes de medicina (2005) Arq Bras Cardiol, 85, pp. 57-6